External funding ask
€22m
Project definition
A modular industrial platform for biostimulants and biofertilizers.
Product platform
- •Liquid potassium humate
- •Fulvic acid concentrates
- •Amino-acid biostimulants
- •Bacillus / Trichoderma biologicals
- •Seed-treatment formulations
Technology basis
- •Alkaline humic extraction
- •Filtration and concentration
- •Industrial fermentation
- •Centrifugation / spray drying
- •Granulation and liquid filling
Commercial scope
- •Domestic farmer channels
- •Regional distributors
- •EU-grade export model
- •Private-label manufacturing
- •Specialty greenhouse / seed treatment
BCL provides product architecture, formulations, QA/QC, regulatory logic and the scale-up package.
Bio Cycle Labs: technology co-partner
BCL contributes the protected technology platform and industrial scale-up expertise — not passive advisory.
- Worldwide patented technology portfolio covering the key platform technologies
- Process architecture for humic / fulvic extraction and microbial biological production
- Formulation library and product strategy for base cash-flow and premium biological products
- QA/QC, microbiology, batch-release, traceability and contamination-control model
- Technology transfer, engineering package, supplier specifications and commissioning support
- Long-term JV governance through technology license, formulation control and technical oversight
The investable asset is not a commodity plant; it is a BCL-enabled technology and product platform.
Technology process model
Proven unit operations combined into an integrated biological-input platform.
- 1
Raw materials
Leonardite / lignite / peat, KOH, molasses / glucose, nutrient media, additives, packaging
- 2
Humic section
Extraction, filtration, ultrafiltration, concentration, blending, liquid filling
- 3
Microbial section
Inoculum lab, seed fermenters, industrial fermenters, centrifuges, spray dryer
- 4
Formulation & filling
Liquid and powder formulations, seed-treatment products, private-label batches
- 5
Quality release
Microbiology lab, contaminant testing, batch traceability, regulatory documentation
Product portfolio and margin ladder
Start with cash-flow products; scale into higher-margin biologicals.
| Segment | Products | Role in model | Indicative EBITDA |
|---|---|---|---|
| Base cash-flow | Potassium humate liquids, fulvic concentrates, amino blends | Fastest market entry; builds distribution and utilization | 15–25% |
| Premium biologicals | Bacillus, Trichoderma, microbial consortia | Main margin expansion and IP-protected differentiation | 30–45% |
| Seed treatment | Seed coating / treatment formulations | High-value channel with strong repeat demand | 40–60% |
| Private label | Contract manufacturing for local and export brands | Utilization stability and distributor lock-in | Case-by-case |
The strongest long-term strategy is not commodity humic alone — the upside is premium microbial and seed-treatment biologicals.
Capacity and ramp-up
The industrial model reaches 48,000 t/year installed capacity and 95% utilization by Year 8.
Total installed capacity: 48,000 t / year
Year 10 output at 95% utilization: 45,600 t / year
Operating footprint and resources
Requirements sized for a mid-scale industrial biological-input facility.
| Area / stream | Requirement | Planning relevance |
|---|---|---|
| Production building | 9,000 m² | Process layout and industrial-zone fit |
| Warehouses | 5,000 m² | Raw materials, packaging and finished goods |
| Labs / R&D | 1,000 m² | QA, microbiology and product release |
| Fresh water | 180,000 m³ / year | Water supply and partial recycling design |
| Electricity | 11.8 GWh / year | Grid connection and energy-efficiency measures |
| Thermal energy | 18.7 GWh / year | Steam, sterilization and drying requirements |
| Truck movements | 5,800–8,400 / year | Inbound raw materials, outbound product, waste streams |
Country selection should prioritize industrial utilities, water access, logistics and proximity to agricultural demand.
Location selection logic
The model can be deployed in any country with the right industrial and agricultural base.
Agricultural demand
Cereals, oilseeds, vegetables, orchards, vineyards, greenhouse or organic sectors
Industrial readiness
Industrial zone, utilities, water, roads, permitting path and labor availability
Market access
Domestic distributors, farmer associations, private-label customers and export corridors
Local partner strength
Site control, operational execution, regulatory navigation and commercial channels
Policy compatibility
Food resilience, farmer support, soil health, bioeconomy and domestic manufacturing priorities
Recommended first step: shortlist 2–3 locations with confirmed utilities, permits and market access.
10-year financial model — consolidated base case
Revenue ramp (€m)
Revenue follows installed capacity, utilization ramp and 2.5% annual sales-price escalation. Preliminary unlevered operating model.
€10.8mY1
€17.4mY2
€22.7mY3
€27.2mY4
€30.6mY5
€32.1mY6
€33.6mY7
€34.8mY8
€35.7mY9
€36.5mY10
Year 1 revenue
€10.8m
Year 5 revenue
€30.6m
Year 10 revenue
€36.5m
Year 10 EBITDA
€12.1m
Year 10 EBITDA margin
33%
Exit EV (8–12× Y10 EBITDA)
€97–145m
Financial model detail
| Year | Revenue €m | OPEX €m | EBITDA €m | Margin | OCF €m |
|---|---|---|---|---|---|
| Y1 | 10.8 | 12.3 | -1.5 | neg. | -1.5 |
| Y2 | 17.4 | 16.0 | 1.4 | 8% | 1.4 |
| Y3 | 22.7 | 18.4 | 4.3 | 19% | 4.0 |
| Y4 | 27.2 | 20.4 | 6.8 | 25% | 6.3 |
| Y5 | 30.6 | 21.7 | 8.9 | 29% | 8.1 |
| Y6 | 32.1 | 22.5 | 9.6 | 30% | 8.8 |
| Y7 | 33.6 | 23.2 | 10.4 | 31% | 9.5 |
| Y8 | 34.8 | 23.7 | 11.1 | 32% | 10.1 |
| Y9 | 35.7 | 24.1 | 11.6 | 33% | 10.6 |
| Y10 | 36.5 | 24.4 | 12.1 | 33% | 11.0 |
- • OCF = operating cash flow after tax, before investor financing.
- • Total external funding ask: €22m, including working capital and pre-operating development.
- • Unlevered cash payback: approximately Year 6 after commercial start under the base case.
External funding required
€22m
Funding can be structured as investor equity, shareholder loan, project debt, convertible instrument, or staged SPV financing.
| Use of funds | Amount |
|---|---|
| Land, site development and permitting | €2.0m |
| Production building and warehouses | €3.6m |
| Humic / fulvic extraction line | €4.0m |
| Fermentation systems | €5.4m |
| Filling, formulation and packaging | €1.6m |
| Utilities, labs, engineering and EPC | €4.0m |
| Initial working capital and launch | €1.4m |
| Total | €22.0m |
Approved introducers or intermediaries may receive a 2–5% success fee from the closed transaction value, subject to mandate, role and applicable law.
Joint venture structure
A replicable SPV model with BCL as technology co-partner and investor as funding partner.
Bio Cycle Labs
Global patented technologies, product architecture, formulation IP, QA/QC model, scale-up package and technical governance
Investor / funding partner
External funding, project-company capitalization, financing discipline and growth capital for scale-up
Local operating partner
Site, permits, workforce, feedstock access, local distribution and farmer relationships
Project company / SPV
Owns local assets, runs production, commercializes products under licensed BCL technology and JV governance
BCL technology remains protected through licensing, formulation governance, QA controls and defined JV rights.
Execution controls
Controls that make the project financeable and protect the technology platform.
- 1.
IP and technology control
BCL license, formula library access rules, change-control and technical governance.
- 2.
Batch release and QA
Microbiology lab, contaminant testing, traceability and product documentation.
- 3.
Operational discipline
Uptime target >92%, OEE >80%, contamination rate <3%, inventory turnover >6×.
- 4.
Commercial resilience
Domestic farmer access plus distributors, private-label contracts and export channels.
- 5.
Localization without dilution
Country-specific raw materials and regulations adapted without exposing core BCL know-how.
Simple enough to build — protected enough to remain a BCL-enabled platform.
Implementation roadmap
From investor alignment to commercial operation in approximately 24 months.
0–90 days
Investor alignment
Confirm country/site shortlist, local partner, target structure and initial funding path.
3–6 months
Feasibility & permits
Feedstock contracts, site feasibility, utilities, regulatory route and bankable model.
6–12 months
Engineering & finance close
Basic engineering, supplier quotations, EPC package and funding close.
12–24 months
Build & commission
Construction, installation, hiring, QA/QC lab setup and pilot batches.
24+ months
Scale & export
Commercial production, farmer demonstration network, private-label deals and export expansion.
The first decision is not construction — it is country, partner and funding alignment.